P591: Negative impact of high body mass index on the efficacy of anti-TNFα agents in patients with Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Hamoir, F.(1)*;De Leuze, F.(1);Denis, M.(1);De Vroey, B.(1);De Suray, N.(1);Burnet, G.(1);Piessevaux, H.(1);Dewit, O.(1);
(1)Cliniques Universitaires Saint-Luc, Gastro-enterology, Brussels, Belgium;
P592: Clinical evaluation of leukocytapheresis compared to vedolizumab in patients with Ulcerative Colitis with contraindications to anti-TNF-alpha: a single-centre experienceECCO’23 CopenhagenYear: 2023
Authors: Ferronato, A.(1)*;Rigno, M.(2);Rodriguez-Castro, K.I.(1);Brozzi, L.(1);Errigo, G.(2);Castelli, M.(2);Baldassarre, G.(1);
(1)Endoscopy Unit Az. ULSS 7 Pedemontana, Medicine, Santorso VI, Italy;(2)Transfusion Medicine Unit Az. ULSS 8 Berica, Diagnostics, Vicenza, Italy;
P593: Impact of immunomodulating treatment modalities, active smoking and (repeated) COVID19 vaccination on S-antibody seroconversion in IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)ECCO’23 CopenhagenYear: 2023
Authors: Geldof, J.(1)*;Truyens, M.(2);Sabino, J.(3);Ferrante, M.(3);Lambert, J.(4);Lapeere, H.(4);Hillary, T.(5);Van Laethem, A.(5);de Vlam, K.(6);Verschueren, P.(6);Padalko, E.(7);Lobaton, T.(2);Vermeire, S.(3);
(1)Ghent University Hospital, Department of Gastroenterology and Hepatology, Gent, Belgium;(2)Ghent University Hospital, Department of Gastroenterology and Hepatology, Ghent, Belgium;(3)University Hospitals Leuven, Department of Gastroenterology and Hepatology- Translational Research in Gastrointestinal Disorders TARGID and Department of Chronic Diseases and Metabolism CHROMETA KU Leuven, Leuven, Belgium;(4)Ghent University Hospital, Department of Dermatology, Ghent, Belgium;(5)University Hospitals Leuven, Department of Dermatology, Leuven, Belgium;(6)University Hospitals Leuven, Department of Rheumatology, Leuven, Belgium;(7)Ghent University Hospital, Department of Laboratory Medicine, Ghent, Belgium;BELCOMID study group
P594: Bowel ultrasound is useful in predicting relapse in patients with Ulcerative Colitis in remissionECCO’23 CopenhagenYear: 2023
Authors: Maeda, M.(1)*;Sagami, S.(1,2);Tashima, M.(1);Yamana, Y.(1);Karashima, R.(1,2);Miyatani, Y.(1);Hojo, A.(1,2);Nakano, M.(1,2);Hibi, T.(1);Kobayashi, T.(1,2,3);
(1)Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan;(2)Department of Gastroenterology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan;(3)Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan;
P595: Time of Therapeutic Drug Monitoring of infliximab during induction and its relationship with clinical remission in Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Muñoz-Villafranca, C.(1);Arreba , P.(1);Gomez, M.(2);Ispizua Madariaga, N.(1)*;Buendia, L.(1);Lopez, M.L.(1);Ugarte, A.(1);de la Fuente, I.(1);Prado, N.(1);Irusta, L.(1);Jimenez, M.A.(1);Santa Cruz, M.(1);Gonzalez, M.(1);Bilbao, A.(3);Ortiz de Zárate, J.(1);
(1)Hospital Universitario Basurto, Gastroenterology, Bilbao, Spain;(2)Hospital de San Eloy, Gastroenterology, Baracaldo, Spain;(3)Hospital Universitario Basurto, Research unit, Bilbao, Spain;
P596: Ustekinumab and anti-TNF agents are equally safe and effective in elderly Crohn's disease patients: A propensity adjusted multi-centre cohort studyECCO’23 CopenhagenYear: 2023
Authors: Gebeyehu, G.G.(1);Broglio, G.(2);Liu, E.(3);Limdi, J.K.(4);Selinger, C.(5);Fiske, J.(1);Razsanskaite, V.(1);Smith, P.J.(1);Flanagan, P.K.(6);Subramanian, S.(7)*;
(1)Liverpool University Hospitals NHS Foundation Trust, Department of Gastroenterology, Liverpool, United Kingdom;(2)IRCCS San Matteo of Pavia- University of Pavia, Department of Internal Medicine, Pavia, Italy;(3)Northern Care Alliance NHS Trust, Section of IBD - Division of Gastroenterology, Manchester, United Kingdom;(4)University of Manchester, Manchester Academic Health Sciences - Faculty of Medicine, Manchester, United Kingdom;(5)Leeds University Teaching Hospital NHS Trust, Department of Gastroenterology, Leeds, United Kingdom;(6)Wirral University Teaching Hospital NHS Trust, Department of Gastroenterology, Wirral, United Kingdom;(7)Cambridge University Hospital NHS Foundation Trust, Department of Gastroenterology, Cambridge, United Kingdom;
P597: Usefulness of histological monitoring in predicting relapse after de-escalation of thiopurines in Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Yamana, Y.(1)*;Sagami, S.(1);Maeda, M.(1);Karashima, R.(1);Miyatani, Y.(1);Hojo, A.(1);Nakano, M.(1);Maeda, I.(2);Hibi, T.(1);Kobayashi, T.(1,3);
(1)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(2)Kitasato University Kitasato Institute Hospital, Department of Diagnostic Pathology, Tokyo, Japan;(3)Kitasato University School of Medicine, Department of Gastroenterology, Kanagawa, Japan;
P598: The utility of the “Low Anterior Resection Syndrome SCORE” in assessing the postoperative outcomes of patients undergoing restorative proctocolectomy with ileal pouch anal-anastomosis for Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Perotti, S.(1)*;Mineccia, M.(1);Daperno, M.(2);Massucco, P.(1);Gonella, F.(1);Ferrero , A.(1);
(1)Ospedale Mauriziano "Umberto I", General and Oncological Surgery, TORINO, Italy;(2)Ospedale Mauriziano "Umberto I", Gastroenterological and Endoscopic Department, Torino, Italy;
P600: Democratic deliberation to assess Veteran preferences for biosimilar medication switching for the treatment of Inflammatory Bowel Disease in a resource-conscious setting.ECCO’23 CopenhagenYear: 2023
Authors: Ryan, K.(1);Hou, J.K.(2,3)*;Baker, J.(4);Krenz, C.(1);De Vries, R.(1);Waljee, A.K.(4,5);
(1)University of Michigan, Center for Bioethics and Social Sciences in Medicine, Ann Arbor, United States;(2)Michael E. DeBakey VA Medical Center, Center for Innovations in Quality- Effectiveness- and Safety, Houston, United States;(3)Baylor College of Medicine, Department of Gastroenterology, Houston, United States;(4)Ann Arbor VA Healthcare System, Center for Clinical Management Research, Ann Arbor, United States;(5)University of Michigan, Department of Gastroenterology, Ann Arbor, United States;
P601: Pneumococcal vaccination in patients with immunomediated inflammatory diseases (IMIDs) using a real-world multidisciplinary projectECCO’23 CopenhagenYear: 2023
Authors: Martins, A.(1);Silva, F.(2);Canelas, G.(2);Ribeiro, L.(3);Pinto, S.(3);Sarmento, A.(3);Magro, F.(4);Ferreira de Abreu, C.M.(5)*;
(1)São João Hospital Center- Porto- Portugal Department of Medicine- Faculty of Medicine- University of Porto- Porto- Portugal Instituto de Inovação e Investigação em Saúde I3S- Portugal d Instituto Nacional de Engenharia Biomédica INEB- Portugal, Infectious Diseases, Porto, Portugal;(2)São João Hospital Center- Porto- Portugal. Department of Medicine- Faculty of Medicine- University of Porto- Porto- Portugal. Instituto de Inovação e Investigação em Saúde I3S- Portugal, Infectious Diseases, Porto, Portugal;(3)São João Hospital Center- Porto- Portugal. Department of Medicine- Faculty of Medicine- University of Porto- Porto- Portugal. Instituto de Inovação e Investigação em Saúde I3S- Portugal, Infectious Diseases, Porto, Portugal;(4)Department of Biomedicine- Unit of Pharmacology and Therapeutics- Faculty of Medicine- University of Porto- Porto- Portugal. Department of Gastroenterology- São João Hospital Center- Porto- Portugal. Clinical Pharmacology Unit- São João Hospital Center- Porto- Portugal, Department of Gastroenterology, Porto, Portugal;(5)São João Hospital Center- Porto- Portugal. Department of Medicine- Faculty of Medicine- University of Porto- Porto- Portugal. Instituto de Inovação e Investigação em Saúde I3S- Portugal., Department of Infectious Diseases, Porto, Portugal;
P602: Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 CopenhagenYear: 2023
Authors: Magro, F.(1)*;Peyrin-Biroulet, L.(2,3);Sands, B.E.(4);Danese, S.(5);Jairath, V.(6);Goetsch, M.(7);Bhattacharjee, A.(8);Wu, J.(9);Ferreira Branquinho, D.(10);Modesto, I.(11);Feagan, B.G.(12);
(1)São João Hospital Center & University of Porto, Gastroenterology, Porto, Portugal;(2)University of Lorraine- Inserm- NGERE, Gastroenterology, Nancy, France;(3)Groupe Hospitalier privé Ambroise Paré - Hartmann- Paris IBD center, Gastroenterology, Neuilly sur Seine, France;(4)Dr. Henry D. Janowitz Division of Gastroenterology- Icahn School of Medicine at Mount Sinai, Gastroenterology, New York- New York, United States;(5)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;(6)Western University, Gastroenterology, London- Ontario, Canada;(7)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(8)Pfizer Healthcare India Pvt. Ltd., Biostatistics, Chennai, India;(9)Pfizer Inc, Biostatistics, Groton- Connecticut, United States;(10)Pfizer Inc, Global Medical Affairs- Gastroenterology, Lisbon, Portugal;(11)Pfizer Inc, Global Medical Affairs- Gastroenterology, Madrid, Spain;(12)University of Western Ontario/Alimentiv Inc, Gastroenterology, London- Ontario, Canada;
P603: Real-world Scottish experience of anti-TNF therapy in paediatric Crohn's disease 2016-2020 against the ECCO-ESPGHAN recommendationsECCO’23 CopenhagenYear: 2023
Authors: Wands , D.(1)*;Scott , G.(2);Wilson , D.C.(1);Hansen , R.(2);Chalmers , I.(3);
(1)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology, Edinburgh, United Kingdom;(2)Royal Hospital for Children, Department of Paediatric Gastroenterology, Glasgow, United Kingdom;(3)Royal Aberdeen Children's Hospital, Department of Paediatric Gastroenterology, Aberdeen, United Kingdom;
P605: Real life efficacy of tofacitinib in different situation in ulcerative colitis: a retrospective worldwide multicentre collaborative studyECCO’23 CopenhagenYear: 2023
Authors: Resál, T.(1);Bacsur, P.(2);Bor, R.(2);Bálint, A.(2);Katsanos, K.(3);Michalopoylos, G.(4);Ribaldone, D.G.(5);Attauabi, M.(6);Mirabella , Z.(7);Yanai, H.(8);Bezzio, C.(9);Castiglione, F.(10);Bar-Gil Shitrit, A.(11);Pugliese, D.(12);Lakatos, P.L.(13,14);Savarino, E.(15);Lukáš, M.(16);Franko, M.(17);Chashkova, E.(18);Molander, P.(19);Nancey, S.(20);Bannon, L.(21);Krznaric, Z.(22);Filip, R.(23);Szamosi, T.(24);Kaštylová, K.(25);Sarlós, P.(26);Ami-Barak, H.(8);Rispo, A.(27);Limdi, J.(28);Kagramanova, A.(29);Szepes, Z.(2);Farkas, K.(2);Molnár, T.(30)*;
(1)University of Szeged, Ist Department of internal medicine, Szeged, Hungary;(2)Szent-Györgyi Albert Medical School- University of Szeged, Department of Medicine, Szeged, Hungary;(3)University of Ioannina School of Health Sciences, Department of Internal Medicine- Faculty of Medicine, Ioannina, Greece;(4)General Hospital of Athens "G. Gennimatas", Gastroenterology Department, Athens, Greece;(5)University of Turin, Department of Medical Science, Turin, Italy;(6)Copenhagen University Hospital - Herlev and Gentofte, Department of gastroenterology, Herlev, Denmark;(7)Copenhagen University Hospital - Amager and Hvidovre, Gastrounit, Hvidovre, Denmark;(8)Rabin Medical Center, Division of Gastroenterology, Tel Aviv, Israel;(9)Rho Hospital- Asst Rhodense, IBD Unit/Gastroenterology Unit, Rho, Italy;(10)Clinical Medicine and Surgery AOU Federico II of Naples, IBD Unit Department, Naples, Italy;(11)Shaare Zedek Medical Center- Hebrew University of Jerusalem, Digestive diseases institute, Jerusalem, Israel;(12)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Rome, Unità Operativa Complessa di Medicina Interna e Gastroenterologia- Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italy;(13)McGill University Health Centre- Montreal General Hospital, Division of Gastroenterology, Montreal, Canada;(14)Semmelweiss University, Department of Internal Medicine and Oncology, Budapest, Hungary;(15)Department of Surgery- Oncology and Gastroenterology, University of Padova, Padova, Hungary;(16)Charles University in Prague, IVth Medical Department, Prague, Czech Republic;(17)University of Ljubljana, Medical Faculty, Ljubljana, Slovenia;(18)Scientific Center of Surgery and Traumatology, Irkutsk, Irkutsk, Russian Federation;(19)Helsinki University Hospital, Abdominal center- Gastroenterology, Helsinki, Finland;(20)Hôpital Lyon Sud, Service d'hépato gastroentérologie, Lyon, France;(21)Tel Aviv medical center, Department of Gastroenterology and Hepatology, Tel Aviv, Israel;(22)Clinical Hospital Centre & School of Medicine Zagreb, Department of Gastroenterology- Hepatology and Nutrition, Zagreb, Croatia;(23)Unit of Clinical Hospital No. 2, Department of Gastroenterology with IBD, Rzeszow, Poland;(24)Military Hospital - State Health Centre- Budapest, Department of Gastroenterology, Budapest, Hungary;(25)ISCARE a.s.- Prague, IBD Clinical and Research Centre, Prague, Czech Republic;(26)University of Pécs, First Department of Medicine, Pécs, Hungary;(27)University "Federico II" of Naples, Gastroenterology IBD Unit, Naples, Italy;(28)Pennine Acute Hospitals NHS Trust, Department of Gastroenterology, Manchester, United Kingdom;(29)Clinical Research Center of Moscow, IBD department, Moscow, Russian Federation;(30)Szent-Györgyi Albert Medical School, Department of Medicine, Szeged, Hungary;
P606: Significant regional differences in referral patterns for bowel resection in Crohn's disease patientsECCO’23 CopenhagenYear: 2023
Authors: Iesalnieks, I.(1)*;Adamou, A.(2);Magdalena, B.(2);Streetz, K.(3);
(1)Evangelisches Krankenhaus Kalk, Department of surgery, Cologne, Germany;(2)Evangelisches Krankenhaus Kalk, Surgery, Cologne, Germany;(3)Evangelisches Krankenhaus kalk, Gastroenterology, Cologne, Germany;
P607: HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Doherty, J.(1)*;Ryan, A.(2);Quinn, E.(2);Dolan, J.(2);Corcoran, R.(3);O' Hara, F.(4);Bailey, Y.(4);McNamara, D.(4);Doherty, G.(5);Kevans, D.(3);
(1)St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland;(2)Genuity Science Ireland Limited, Inflammatory Bowel Disease, Dublin, Ireland;(3)St James Hospital, Department of Gastroenterology, Dublin, Ireland;(4)Tallaght University Hospital- Dublin- Ireland, Department of Gastroenterology, Dublin, Ireland;(5)Centre for Colorectal Disease- St Vincent's University Hospital & School of Medicine- University College Dublin, Department of Gastroenterology and School of Medicine- University College Dublin, Dublin, Ireland;Trinity Academic Gastroenterology Group School of Medicine Trinity College Dublin Ireland. Wellcome-HRB Clinical Research Facility St James's Hospital Dublin Ireland. INITIative IBD research network (www.initiativeibd.ie)
P608: Time to onset of effect of biologics and small molecules in moderate-to-severe or acute severe ulcerative colitis – a systematic review and network meta-analysisECCO’23 CopenhagenYear: 2023
Authors: Attauabi, M.(1,2)*;Dahl, E.K.(1);Burisch, J.(2,3);Gubatan, J.(4);Nielsen, O.H.(1);Seidelin, J.B.(1);
(1)Copenhagen University Hospital - Herlev and Gentofte, Department of Gastroenterology and Hepatology, Herlev, Denmark;(2)Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents- and Adults, Hvidovre, Denmark;(3)Copenhagen University Hospital - Amager and Hvidovre- Hvidovre, Gastrounit- Medical Section, Hvidovre, Denmark;(4)Stanford University School of Medicine, Division of Gastroenterology and Hepatology, Stanford, United States;
P609: Impact of prior biologic exposure on durability of recaptured response to ozanimod during the True North open-label extension studyECCO’23 CopenhagenYear: 2023
Authors: Colombel, J.F.(1)*;Rubin, D.T.(2);Vermeire, S.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Dignass, A.(5);Regueiro, R.(6);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(2)University of Chicago Medicine Inflammatory Bowel Disease Center, Gastroenterology, Chicago, United States;(3)University of Leuven, Chronic Diseases and Metabolism, Leuven, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)Agaplesion Markus Hospital- Goethe University, Medicine, Frankfurt, Germany;(6)Cleveland Clinic, Digestive Disease and Surgery Institute, Cleveland, United States;
P610: Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR)ECCO’23 CopenhagenYear: 2023
Authors: Irving, P.M.(1);Hur, P.(2)*;Gautam, R.(3);Guo, X.(4);Vermeire, S.(5);
(1)Guy's and St Thomas' Hospital- Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;(2)Pfizer Inc., Inflammation and Immunology, New York, United States;(3)EVERSANA Pvt. Ltd, HEOR/Real-world Evidence, Mumbai, India;(4)Pfizer Inc., Gastroenterology- Inflammation and Immunology, Collegeville- PA, United States;(5)University Hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;
P611: COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS. ANTI-TNFs IN CROHN'S DISEASE BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)ECCO’23 CopenhagenYear: 2023
Authors: Muñoz Nuñez, J.F.(1)*;Rodríguez, C.(2);Gisbert, J.P.(3);Bernardo, S.(4);Aparicio, J.(5);Tagarro, I.(5);Casellas, F.(6);
(1)Complejo Asistencial Universitario de Salamanca, Digestive Service, Salamanca, Spain;(2)Complejo Hospitalario de Navarra, Gastroenterology Unit, Pamplona, Spain;(3)Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa IIS-Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Madrid, Spain;(4)Hospital de Santa Maria- Centro Hospitalar Lisboa Norte, Serviço de Gastrenterologia e Hepatologia, Lisbon, Spain;(5)Takeda Farmacéutica España, Medical Department, Madrid, Spain;(6)Hospital Universitari Vall d'Hebron, Crohn-Colitis Care Unit UACC, Barcelona, Spain;
